Literature DB >> 18008149

Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism: the interaction between tramadol and its active metabolite on micro-opioid agonism and monoamine reuptake inhibition, in the rat.

Horst Beier1, María J Garrido, Thomas Christoph, Dirk Kasel, Iñaki F Trocóniz.   

Abstract

PURPOSE: To establish a semi-mechanistic pharmacokinetic/pharmacodynamic (pk/pd) model for racemic tramadol (T) integrating all the components with a significant contribution to T effects in rats, using cold allodynia in the Bennett model of neuropathic pain.
METHODS: Male Sprague-Dawley rats (n=53) were randomly allocated in six groups receiving saline, racemic T (5 mg/kg), RR-T (5 mg/kg), SS-T (5 mg/kg), RR-O-demethyltramadol [RR-M1 (1 mg/kg)] or SS-M1 (30 mg/kg) in two h intravenous infusion.
RESULTS: The mu-opioid effects of RR-M1 (E(RR-M1)) were described with an effect compartment model. Contribution to analgesic response of RR-T resulted negligible. The monoamine re-uptake inhibition effects (ESS-M1,T) were modelled as an indirect response model incorporating a competitive interaction between SS-T and SS-M1. ERR-M1 and ESS-M1,T were finally considered as a two independent stimuli converging into a single and common antinoceptive stimulus. The estimates of the steady-state plasma concentrations eliciting half of maximum response for RR-M1, SS-T, and SS-M1 were 20.2, 230, and 869 ng/ml, respectively. RR-M1 is the main active component, but SS-T having a significant contribution.
CONCLUSION: Cold allodynia in the Bennett model has proven an adequate experimental set up to develop complex pk/pd models in analgesia involving different mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18008149     DOI: 10.1007/s11095-007-9489-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  31 in total

1.  Response surface model for anesthetic drug interactions.

Authors:  C F Minto; T W Schnider; T G Short; K M Gregg; A Gentilini; S L Shafer
Journal:  Anesthesiology       Date:  2000-06       Impact factor: 7.892

Review 2.  Animal models of nociception.

Authors:  D Le Bars; M Gozariu; S W Cadden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 25.468

3.  Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats.

Authors:  M Valle; M J Garrido; J M Pavón; R Calvo; I F Trocóniz
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

4.  Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics.

Authors:  María J Garrido; Walid Habre; Ferdinand Rombout; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

5.  Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling.

Authors:  M Gårdmark; M Hammarlund-Udenaes
Journal:  Pain       Date:  1998-02       Impact factor: 6.961

6.  Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity.

Authors:  Maria J Garrido; Onintza Sayar; Cristina Segura; Javier Rapado; Maria Carmen Dios-Vieitez; Maria Jesus Renedo; Inaki F Troconiz
Journal:  J Pharmacol Exp Ther       Date:  2003-02-11       Impact factor: 4.030

7.  Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro.

Authors:  B Driessen; W Reimann; H Giertz
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

8.  Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.

Authors:  R B Raffa; E Friderichs; W Reimann; R P Shank; E E Codd; J L Vaught
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

9.  Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.

Authors:  C P Watson; N Babul
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

10.  Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial.

Authors:  Joseph S Gimbel; Patricia Richards; Russell K Portenoy
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

View more
  6 in total

1.  Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects.

Authors:  Víctor Mangas-Sanjuan; José Martín Pastor; Jens Rengelshausen; Roberta Bursi; Iñaki F Troconiz
Journal:  Br J Clin Pharmacol       Date:  2016-04-14       Impact factor: 4.335

Review 2.  The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.

Authors:  Thomas M Tzschentke; Thomas Christoph; Babette Y Kögel
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

3.  Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.

Authors:  Nieves Vélez de Mendizábal; Dalia Vásquez-Bahena; Juan M Jiménez-Andrade; Mario I Ortiz; Gilberto Castañeda-Hernández; Iñaki F Trocóniz
Journal:  AAPS J       Date:  2012-09-12       Impact factor: 4.009

Review 4.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

5.  The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.

Authors:  Tarjinder Sahota; Meindert Danhof; Oscar Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-04-14       Impact factor: 2.745

6.  A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans.

Authors:  Kelly E Dunn; Cecilia L Bergeria; Andrew S Huhn; Eric C Strain
Journal:  Front Psychiatry       Date:  2019-09-26       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.